Business
Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812
- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association - NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) today announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies (DLB). CT1812 is an experimental, orally delivered small molecule therapeutic intended to address the underlying biology of DLB. “Dementia with Lewy bodies is a devastating disease that has no disease-modifying treatments and impacts millions of people around the globe, yet remains under-funded and under-researched,” stated James E. Galvin, MD, MPH, the director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and primary investigator in the Phase 2 study. “This Phase 2 study provides me and my colleagues at other sites in the Lewy Body Dementia Consortium an opportunity to investigate a unique mechanism of action that has the potential to impact the progression of DLB. I’m looking forward to working with the team at Cognition to assess this novel medication.” DLB is a multi-faceted disorder characterized by the accumulation of α-synuclein fibrils, the major constituent of the Lewy bodies that occur inside brain neurons, which exert deleterious effects across brain structures. In addition, many patients with DLB also have a buildup of Aβ oligomers. Together, the accumulation of pathogenic proteins in DLB is believed to be due in part to a failure of autophagy and other key cellular functions. Further evidence suggests that these processes are regulated by the sigma-2 (σ-2) receptor, which is the biological target of CT1812. Cognition has previously published results supporting the use of σ-2 receptor modulators such as CT1812 to protect neurons from the toxic insults from α-synuclein and Aβ oligomers. It is anticipated that its mechanism of action may thus enable CT1812 to address the dual assault from α-synuclein and Aβ oligomers in patients with DLB. Cognition anticipates enrolling 120 adults between 50 and 80 years of age with a DLB diagnosis, who will be randomized to receive placebo or one of two daily (QD) doses of CT1812 for six months. In...